Rituximab (Rituxan) Immunogeni

In Vitro Immunogenicity Risk Assessment of Therapeutic Proteins in Preclinical Setting

Immunogenicity against therapeutic proteins is a clinical problem in the successful treatment of many diseases and, as such, immunogenicity risk assessment in preclinical setting would be useful to improve safety and efficacy of protein-based

CANDOR BIOSCIENCE: 关于ELISA板稳定性的技术探讨与比较

部分。它们的错误折叠，如天然结构的丢失，是任何分析的一个重大问题，因为它会引起抗体结合部位、抗体的抗原结合区或抗原的表位的改变，这两者都是待测物结合所必需的。因此，捕获分子无法结合待测物，甚至可能由于暴露天然未暴露的氨基酸序列和结构而发生非特异性结合，导致诊断试验显示错误的结果。由于表面效应引起的空间结构和构象的改变，抗体在包被过程中会发生错误折叠。在ELISA微孔板中，只有3-10%的包被抗体具有良好的定向性和与待测物结合的功能活性。抗原包被也有类似的情况。在大多数情况下，很少量的活性成分就足以完成一次检测

Construction and Characterization of Minibodies for Imaging and Therapy of Colorectal Carcinomas

(1 ,2 ). Chimerization or humanization can also increase the ability of murine MAbs to interact with the human immune system. The anti-lymphoma and anti-breast cancer antibodies Rituxan™ (Rituximab) and Herceptin™ (Trastuzumab) are robust examples of this path